Current Product Partners
and Available Partnership Opportunities
Through in-licensing relationships, research collaborations and strategic alliances that complement and extend the Staccato® technology, Alexza is interested in developing partnerships that have the potential to create superior products and improve patients’ lives.
ADASUVE® Commercial Territories
ADASUVE® (AZ-004) – Staccato Loxapine
Ferrer holds commercial rights in Europe, Latin America, Russia, the CIS countries, the Middle East and North Africa countries, Korea, Philippines, and Thailand.
Galen holds commercial rights in the United States.
Available for licensing in all other territories
Partnered Development Programs
AZ-002 – Staccato alprazolam
Engage Therapeutics holds worldwide development and commercial rights.
AZ-003 – Staccato fentanyl for cancer breakthrough pain
AZ-007 – Staccato zaleplon for middle of the night awakening
Available for licensing in all territories
To discuss partnership and licensing opportunities, please contact our Business Development Group.